MARKETS
S&P 5007,376.86+0.31%
NASDAQ 10026,989.99+1.35%
XBI152.21+2.57%
IBB213.63+1.73%
DOW 3051,285.73−0.46%
FTSE 10010,673.94−1.01%
Biotechnology Daily

Karyopharm Takes Selinexor to ASH Amid Equity Wipeout Warning

Karyopharm will present selinexor trial data at ASH, but its Chapter 11 plan provides no payment to existing common or preferred shareholders.

Maya Sterling 3 min read
Gloved hands carefully handling a blood sample in a medical or laboratory environment.

Karyopharm announced that 48-week data from its Phase 3 SENTRY myelofibrosis trial will receive an oral presentation at ASH 2026 while its Chapter 11 plan provides no recovery for existing shareholders.

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) will bring longer-term selinexor findings to the American Society of Hematology meeting as the drugmaker warns that existing shareholders face a complete loss under its Chapter 11 plan.

The company announced Nov. 4 that its Phase 3 SENTRY and Phase 2 SENTRY-2 myelofibrosis studies were selected for oral presentations at ASH 2026. A separate combination study in multiple myeloma will receive a poster presentation, according to its PR Newswire announcement.

The clinical program and the stock carry distinct implications: evidence supporting a medicine's development does not establish a recovery for shareholders when the restructuring plan explicitly excludes one.

Chapter 11 plan separates drug progress from equity value

Karyopharm said its voluntary Chapter 11 cases remain pending. Its plan provides no payment or other distribution to holders of common or preferred stock, and the company expects existing equity securities to have no value.

The company also expects its common stock to be delisted from the Nasdaq Global Select Market. It cautioned that securities prices during the bankruptcy proceedings may bear little or no relationship to any eventual recovery.

The company also expects its common stock to be delisted from the Nasdaq Global Select Market.

For investors, that makes the conference announcement a development update rather than evidence that existing shares will participate in selinexor's potential future value. The company's stated risks also include continued access to operating capital during Chapter 11 and the possibility that drug development may not continue.

SENTRY extends the view beyond its primary endpoints

The SENTRY presentation will cover week 48 findings. The randomized Phase 3 trial enrolled 353 patients with myelofibrosis who had not previously received a JAK inhibitor, a class of medicines used to treat the disease. It compares once-weekly 60 mg selinexor plus ruxolitinib with placebo plus ruxolitinib.

The study's co-primary endpoints assess a spleen-volume reduction of at least 35% at week 24 and the average change in absolute total symptom score over 24 weeks. The later follow-up therefore addresses how treatment activity develops beyond the primary assessment period.

Chief Medical Officer Reshma Rangwala said the combination showed continuing benefit through week 48. SENTRY results were previously presented at the 2026 American Society of Clinical Oncology meeting and European Hematology Association congress, and published in the Journal of Clinical Oncology. Selection for another presentation is not itself a regulatory approval.

Monotherapy and myeloma studies test different uses

SENTRY-2 evaluates selinexor initially as a standalone treatment in patients with myelofibrosis, low platelet counts and no prior JAK-inhibitor treatment. Its primary endpoint is a spleen-volume reduction of at least 35% at week 24.

The protocol permits adding a JAK inhibitor if spleen reduction falls below specified thresholds at weeks 12 or 24. That design makes treatment exposure important when interpreting later outcomes: results after an add-on therapy are not equivalent to results achieved with selinexor alone. Rangwala said early findings from the weekly 60 mg cohort support monotherapy activity.

The multiple myeloma poster concerns STOMP Arm 12, which combines selinexor, mezigdomide and dexamethasone in patients whose disease has returned or resisted treatment after substantial prior therapy. The study assesses dosing, response and safety. Although selinexor is already marketed as XPOVIO for certain multiple myeloma uses, that does not establish approval for this investigational combination or for myelofibrosis.

Key facts

  • Company: Karyopharm Therapeutics; symbol KPTI; Nasdaq delisting expected.
  • ASH presentations: Oral presentations for SENTRY and SENTRY-2; a poster for STOMP Arm 12.
  • Phase 3 follow-up: SENTRY presentation covers week 48 data from a 353-patient trial.
  • Shareholder recovery: Chapter 11 plan provides no payment or distribution to common or preferred stockholders.

Sources

Photo: Los Muertos Crew · Pexels Licence — source

Filed under Biotechnology Daily

More on Biotechnology Daily

See all →